VECTIBIX in combination with oxaliplatin-based chemotherapy is indicated for the treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC).
VECTIBIX is indicated for the treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC) in combination with irinotecan-based chemotherapy.
VECTIBIX monotherapy is indicated for the treatment of patients with wild-type RAS mCRC after failure of standard chemotherapy.